The FDA has approved the CD19+ B-cell targeted therapy inebilizumab-cdon (Uplizna, Amgen) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine ...

Please provide your email address to receive an email when new articles are posted on . FDA approves inebilizumab-cdon for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine ...

Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. The MINT trial ...

The leading approach to the simplex method, a widely used technique for balancing complex logistical constraints, can’t get any better. In 1939, upon arriving late to his statistics course at the ...

Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point they rarely leave their home and are unable to work and build meaningful ...

Static ultrasound guidance is used to select and mark the site of needle insertion immediately before the procedure takes place. Dynamic ultrasound guidance, in contrast, is used to directly visualize ...

The way cardiovascular care is delivered in the US is changing rapidly. Procedures once limited to hospitals are now increasingly performed in outpatient clinics such as ambulatory surgery centers and ...

ROOTSTOWN, Ohio--(BUSINESS WIRE)--#BioMendics--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a ...

Johnson Controls' Simplex Incident Manager, a complete web-based fire alarm management workstation for campuses and large facilities. The solution enables facility teams to monitor and manage their ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease ...